Patau syndrome genome > down syndrome genome > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Patau syndrome genome

Non-Invasive Genetic Testing Can Safely Detect the Patau Syndrome Genome

Learning that you are expecting a baby is one of life's most joyous momentsâ€but it can also come attached with some anxiety when you learn about common pregnancy risks and abnormalities. Expectant parents routinely undergo fetal testing to screen for the presence of the Patau syndrome genome. As an alternative to invasive and potentially risky procedures including amniocentesis for Patau Syndrome screening, Eurofins Biomnis offers non-invasive genetic testing with quick, accurate results. The test draws analysis from a maternal blood sample, and can be prescribed starting at only 10 weeks of pregnancy. By opting for this non-invasive genetic testingoption, the Patau syndrome genome may be detected or ruled out.

Although most expectant parents are aware of risks for fetal genetic defects, and wonder whether the Down syndrome genome can be easily detected, many people are unaware that non-invasive genetic testing during pregnancyis an option. However, effective and entirely safe non-invasive testing methods are now readily available. Safe, reliable, and rapid, the test can be obtained starting in only the tenth week of pregnancy. It simultaneously detects risks for the Down syndrome genome as well as for trisomies 13 and 18â€offering peace of mind from earlier on. Explore the website to learn more about why this groundbreaking new screening methodmay be the right option for you.

When it comes to prenatal screening and diagnosis, including for the Edwards Syndrome genome, it can be easy to assume that non-invasive DNA testing must be at least as complicated as traditional, invasive procedures such as amniocentesis. In reality, the innovative testing kit developed by Eurofins Biomnis is remarkably simple to prescribe and administer: it can be taken at your healthcare provider's office or at a partner laboratory. With results of the blood test available in around 7 working days, NIPT by Eurofins Biomis has been found to reduce unnecessary invasive sampling by up to 95%, and help detect or rule out abnormalities such as the Edwards' Syndrome genome.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%